PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2007-05-085159PMID 18203952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma

  2007cited by this paper
• The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

  2007cited by this paper
• RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma.

  2007cited by this paper
• The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.

  2007cited by this paper
• PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection

  2006cited by this paper
• Corrigendum: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade

  2006cited by this paper
• Programmed Death-1 (PD-1) is a Marker of Germinal Center-associated T Cells and Angioimmunoblastic T-Cell Lymphoma

  2006cited by this paper
• PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

  2006cited by this paper
• Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

  2006cited by this paper
• Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

  2006cited by this paper
• Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells

  2005cited by this paper
• Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.

  2005cited by this paper
• Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer

  2005cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor‐κB p52, which is associated with hyperphosphorylated Bcl‐3

  2005cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

  2004cited by this paper
• Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease

  2004cited by this paper
• High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease.

  2003cited by this paper
• Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B‐cell lymphoma

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

  2001cited by this paper
• Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas.

  2000cited by this paper

• B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.

  2025cites this paper
• Nivolumab for relapsed and refractory classical Hodgkin lymphoma: retrospective single center analysis

  2025cites this paper
• Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies

  2025cites this paper
• Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

  2025cites this paper
• Increased incidence of Hodgkin lymphoma with decreased association with Epstein-Barr virus in Taiwan: a shift toward Western style.

  2025cites this paper
• PD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors

  2025cites this paper
• The biology of classical Hodgkin lymphoma.

  2024cites this paper
• Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma

  2024cites this paper
• Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

  2024cites this paper
• Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

  2024cites this paper
• T cell exhaustion in human cancers.

  2024cites this paper
• Advances in Hodgkin lymphoma research.

  2024cites this paper
• Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1.

  2024cites this paper
• Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis

  2024cites this paper
• PD-1 endocytosis unleashes the cytolytic potential of check-point blockade in tumor immunity

  2024cites this paper
• Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art

  2024cites this paper
• How lactate affects immune strategies in lymphoma

  2024cites this paper
• PD-L1 and PD-1 in Immune Regulation and Their Implications in Blood Cancers

  2024cites this paper
• Computational Identification of Migrating T cells in Spatial Transcriptomics Data

  2024cites this paper
• Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network

  2023cites this paper
• METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment

  2023cites this paper
• The current state and future of T-cell exhaustion research

  2023cites this paper
• Advances in the treatment of Hodgkin's lymphoma (Review)

  2023cites this paper
• Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

  2023cites this paper
• PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma

  2023cites this paper
• Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy.

  2023cites this paper
• Classical Hodgkin Lymphoma: From Past to Future—A Comprehensive Review of Pathophysiology and Therapeutic Advances

  2023cites this paper
• PD‐1 expression on tumour‐infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B‐cell lymphoma

  2023cites this paper
• Role of CD68 in the tumor immune microenvironment in Hodgkin’s lymphoma

  2023cites this paper
• Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma

  2023cites this paper
• Classical Hodgkin Lymphoma: Tumor Structure and Prognostic Value of the Immune Microenvironment

  2023cites this paper
• FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC

  2023cites this paper
• EBV-induced T-cell responses in EBV-specific and nonspecific cancers

  2023cites this paper
• Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma

  2023cites this paper
• Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment

  2022cites this paper
• PET/CT in Hodgkin Lymphoma: An Update.

  2022cites this paper
• Spatial immune heterogeneity of hypoxia-induced exhausted features in high-grade glioma

  2022cites this paper
• IL-6/STAT3 Signaling Axis Enhances and Prolongs Pdcd1 Expression in Murine CD8 T Cells.

  2022cites this paper
• Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway

  2022cites this paper
• One arrow for two targets: potential co-treatment regimens for lymphoma and HIV.

  2022cites this paper
• IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma

  2022cites this paper
• Peptide-MHC complexes: dressing up to manipulate T cells against autoimmunity and cancer.

  2022cites this paper
• Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients

  2022cites this paper
• A review of pathobiology and therapies for classic Hodgkin lymphoma.

  2022cites this paper
• CMAR_A_351383 1267..1281

  2022cites this paper
• Hodgkin Lymphoma: Biology and Differential Diagnostic Problem

  2022cites this paper
• PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis

  2022cites this paper
• Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies

  2022cites this paper
• Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring

  2022cites this paper
• Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma

  2022cites this paper
• PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?

  2022cites this paper
• Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity

  2022cites this paper
• Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview

  2021cites this paper
• Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas.

  2021cites this paper
• Hodgkin Lymphoma: A Special Microenvironment

  2021cites this paper
• Adoptive T-cell therapy for Hodgkin lymphoma

  2021cites this paper
• Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

  2021cites this paper
• New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond

  2021cites this paper
• PD-1 and PD-L2: Do they have prognostic value in lymphomas? PD-1 ve PD-L2: Lenfomalarda prognostik değeri var mı?

  2021cites this paper
• PD-1、TIM-3、LAG-3、BTLA在结外NK/T细胞淋巴瘤中的表达及其预后价值

  2021cites this paper
• Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy

  2021cites this paper
• Immune checkpoint inhibition in classical hodgkin lymphoma

  2021cites this paper
• Syncytial Variant of Nodular Sclerosis Hodgkin Lymphoma: An Under-emphasized Variant.

  2021cites this paper
• Classic Hodgkin lymphoma in Guatemalan children of age less than six years: analysis of immune regulatory pathways and the tumor microenvironment

  2021cites this paper
• Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.

  2021cites this paper
• Molecular biology of Hodgkin lymphoma

  2021cites this paper
• Immuno-oncology: are TAM receptors in glioblastoma friends or foes?

  2021cites this paper
• PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.

  2021cites this paper
• Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1

  2021cites this paper
• Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment

  2020cites this paper
• Immune checkpoints in hematologic malignancies: What made the immune cells and clinicians exhausted!

  2020cites this paper
• PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas

  2020cites this paper
• Microenvironment, Cross-Talk, and Immune Escape Mechanisms

  2020cites this paper
• PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma

  2020cites this paper
• Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1

  2020cites this paper
• Hodgkin Lymphoma and PD-1 Blockade

  2020cites this paper
• Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.

  2020cites this paper
• Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy

  2020cites this paper
• Phosphorylation: A Fast Switch For Checkpoint Signaling.

  2020cites this paper
• Advances in targeted therapy for malignant lymphoma

  2020cites this paper
• Clinicopathological and prognostic significance of PD‐1/PD‐L1 axis expression in patients with tongue squamous cell carcinoma

  2020cites this paper
• Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

  2020influential citation
• Other New Agents for Hodgkin Lymphoma

  2020cites this paper
• EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.

  2020cites this paper
• PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma

  2020cites this paper
• Porcine genome engineering for xenotransplantation.

  2020cites this paper
• Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas.

  2020cites this paper
• Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma

  2020cites this paper
• The BTLA and PD‐1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells

  2020influential citation
• iPSC-derived Rejuvenated T-cell Therapy for Extranodal NK/T-cell Lymphoma, Nasal Type

  2020cites this paper
• Immunopathology and Immunotherapy of Hodgkin Lymphoma

  2020cites this paper
• An Autopsy Case of an Elderly Patient with Classic Hodgkin Lymphoma Presenting with a Plethora of Clinical Symptoms and Signs

  2020cites this paper
• The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes

  2020cites this paper
• Epstein–Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma

  2020cites this paper
• The role of trogocytosis in immune surveillance of Hodgkin lymphoma

  2020cites this paper
• Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma: Phase 1 Results of a Multicenter Phase 1/2 Clinical Trial

  2020cites this paper
• Juntendo Medical Journal

  2020cites this paper
• Expression of PD‐1/PD‐L1 in children's classical Hodgkin lymphomas

  2019cites this paper
• Could the menagerie of the gut microbiome really cure cancer? Hope or hype

  2019cites this paper
• The Tumor Microenvironment in Post-Transplant Lymphoproliferative Disorders

  2019cites this paper